SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Aldebaran Capital, LLC

CIK 0001448430 · 10293 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46290 · 317-818-7827

Reported Value
$105M
Q4 2024
Positions
37
Filings on Record
14
2019–present window
Filed
Feb 12, 2025
original filing

Summary

Aldebaran Capital, LLC reported $105M in U.S.-listed holdings across 37 positions for Q4 2024.

Its largest position, BRK/B, represents 18.6% of the portfolio.

Compared with Q3 2024, the fund opened 3 new positions and exited 3.

Portfolio Metrics

Turnover
+5.4%
vs prior filed quarter
Top-10 Concentration
+71.8%
share of reported value
Largest Position
+18.6%
Berkshire Hathaway
New / Exited
3 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $97MQ4 ’22Q1 ’23: $98MQ2 ’23: $97MQ2 ’23Q3 ’23: $98MQ4 ’23: $98MQ4 ’23Q1 ’24: $105MQ2 ’24: $107MQ2 ’24Q3 ’24: $110MQ4 ’24: $105MQ4 ’24Q1 ’25: $106MQ2 ’25: $101MQ2 ’25Q3 ’25: $109MQ4 ’25: $112MQ4 ’25Q1 ’26: $131Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.1%ETP: 7.9%Other: 7.8%Equity WRT: 0.2%
  • Common Stock · 84.1% · $89M
  • ETP · 7.9% · $8M
  • Other · 7.8% · $8M
  • Equity WRT · 0.2% · $219,877

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SIRISIRIUS XM HOLDINGS INCNEW+43.1K43.1K+$982,976$982,976
EPIEURESSA PHARMA INCNEW+397.5K397.5K+$711,566$711,566
OKURONKURE THERAPEUTICS INCNEW+45.6K45.6K+$391,919$391,919
ANTXAN2 THEREAPEUTICS INCADDED+243.2K343.7K+$366,749$474,284
RENEO PHARMACEUTICALS INCSOLD OUT−452.1K0−$768,597$0
ABRDN ETFSSOLD OUT−13.3K0−$319,995$0
EXMOCEXXON MOBIL CORPSOLD OUT−1.9K0−$223,656$0
PATKPATRICK INDS INCADDED+4.6K14.3K−$189,088$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

35 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BRK/BBERKSHIRE HATHAWAY INC DELCL B NEW · CL A19.89%$21M43.2K
2MSFTMICROSOFT CORPhistory →COM9.28%$10M23.2K
3OXYOCCIDENTAL PETE CORPCOM · star W EXP 08/03/2028.16%$9M177.4K
4BUNGE LIMITEDCOM7.25%$8M98.1K
5BACBANK AMERICA CORPhistory →COM5.89%$6M141.0K
6LLYLILLY ELI & COhistory →COM5.71%$6M7.8K
7ISHARES TR RUS MDCP VALETF4.97%$5M40.4K
8SUSUNCOR ENERGY INC NEWhistory →COM4.24%$4M125.0K
9CO2ACATO CORP NEWhistory →CL A3.99%$4M1.08M
10CHVCHEVRON CORP NEWhistory →COM3.93%$4M28.6K
11ABRDN ETFSBBRG ALL COMD K12.89%$3M154.0K
12JPMJPMORGAN CHASE & COhistory →COM2.71%$3M11.9K
13ACRSACLARIS THERAPEUTICS INChistory →COM2.40%$3M1.02M
14RELLRICHARDSON ELECTRS LTDhistory →COM1.96%$2M147.1K
15TECXTECTONIC THERAPEUTIC INChistory →COM1.81%$2M41.2K
16ENBENBRIDGE INChistory →COM1.74%$2M43.1K
17BACVERIZON COMMUNICATIONS INChistory →COM1.55%$2M40.7K
18FCXFREEPORT-MCMORAN INChistory →CL B1.15%$1M31.7K
19PATKPATRICK INDS INChistory →COM1.13%$1M14.3K
209HIHILLENBRAND INChistory →COM1.13%$1M38.5K
21CENXCENTURY ALUM COhistory →COM1.07%$1M62.0K
22AMLXAMYLYX PHARMACEUTICALS INCCOM0.94%$993,206262.8K
23SIRISIRIUS XM HOLDINGS INCCOMMON STOCK0.93%$982,97643.1K
24IESCIES HLDGS INCCOM0.79%$827,7544.1K
25PMVPPMV PHARMACEUTICALS INCCOM0.72%$758,307502.2K
26EPIEURESSA PHARMA INCCOM NEW0.68%$711,566397.5K
27TECK/BTECK RESOURCES LTDCOM0.50%$530,33513.1K
28ANTXAN2 THEREAPEUTICS INCCOM0.45%$474,284343.7K
29ABXBARRICK GOLD CORPCOM0.41%$434,77528.1K
30OKURONKURE THERAPEUTICS INCCOM CL A0.37%$391,91945.6K
31DUKE ENERGY CORP NEWCOM NEW0.37%$387,8643.6K
32MBINMERCHANTS BANCORP INDCOM0.35%$369,25910.1K
33FFORD MTR CO DELCOM0.24%$253,93525.6K
34PGPROCTER AND GAMBLE COCOM0.20%$211,3141.3K
35GENERAL ELECTRIC COCOM0.20%$209,4881.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$131M43May 7, 202613F-HRchanges · EDGAR ↗
Q4 2025$112M35Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M33Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M34Aug 12, 202513F-HRchanges · EDGAR ↗
Q1 2025$106M41May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$105M37Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$110M37Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$107M36Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$105M33May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$98M31Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$98M33Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$97M33Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$98M34May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$97M34Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.